drugset / Trial / NCT02156388
Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors
RandomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to access the safety, tolerance and Pharmacokinetic/Pharmacodynamic(PK/PD) of single subcutaneous(SC) injection of GW003 in patients with metastatic tumors.
Timeline
- Start
- 2013-08
- Primary completion
- 2015-02
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GW003 | Protein / enzyme biologic | 50 ug/kg | Subcutaneous |
| Subject | GW003 | Protein / enzyme biologic | 150 ug/kg | Subcutaneous |
| Subject | GW003 | Protein / enzyme biologic | 300 ug/kg | Subcutaneous |
| Subject | GW003 | Protein / enzyme biologic | 400 ug/kg | Subcutaneous |
| Subject | GW003 | Protein / enzyme biologic | 500 ug/kg | Subcutaneous |
| Subject | GW003 | Protein / enzyme biologic | 600 ug/kg | Subcutaneous |